BACKGROUND: Pneumococcus, meningococcus, and Haemophilus influenzae cause a similar spectrum of infections in the ear, lung, blood, and brain. They share cross-reactive antigens that bind to the laminin receptor of the blood-brain barrier as a molecular basis for neurotropism, and this step in pathogenesis was addressed in vaccine design. METHODS: Biologically active peptides derived from choline-binding protein A (CbpA) of pneumococcus were identified and then genetically fused to L460D pneumolysoid. The fusion construct was tested for vaccine efficacy in mouse models of nasopharyngeal carriage, otitis media, pneumonia, sepsis, and meningitis. RESULTS: The CbpA peptide-L460D pneumolysoid fusion protein was more broadly immunogenic than pneumolysoid alone, and antibodies were active in vitro against Streptococcus pneumoniae, Neisseria meningitidis, and H. influenzae. Passive and active immunization protected mice from pneumococcal carriage, otitis media, pneumonia, bacteremia, meningitis, and meningococcal sepsis. CONCLUSIONS: The CbpA peptide-L460D pneumolysoid fusion protein was broadly protective against pneumococcal infection, with the potential for additional protection against other meningeal pathogens.
BACKGROUND: Pneumococcus, meningococcus, and Haemophilus influenzae cause a similar spectrum of infections in the ear, lung, blood, and brain. They share cross-reactive antigens that bind to the laminin receptor of the blood-brain barrier as a molecular basis for neurotropism, and this step in pathogenesis was addressed in vaccine design. METHODS: Biologically active peptides derived from choline-binding protein A (CbpA) of pneumococcus were identified and then genetically fused to L460D pneumolysoid. The fusion construct was tested for vaccine efficacy in mouse models of nasopharyngeal carriage, otitis media, pneumonia, sepsis, and meningitis. RESULTS: The CbpA peptide-L460D pneumolysoid fusion protein was more broadly immunogenic than pneumolysoid alone, and antibodies were active in vitro against Streptococcus pneumoniae, Neisseria meningitidis, and H. influenzae. Passive and active immunization protected mice from pneumococcal carriage, otitis media, pneumonia, bacteremia, meningitis, and meningococcal sepsis. CONCLUSIONS: The CbpA peptide-L460D pneumolysoid fusion protein was broadly protective against pneumococcal infection, with the potential for additional protection against other meningeal pathogens.
Authors: Rensheng Luo; Beth Mann; William S Lewis; Arthur Rowe; Richard Heath; Michael L Stewart; Agnes E Hamburger; Siva Sivakolundu; Eilyn R Lacy; Pamela J Bjorkman; Elaine Tuomanen; Richard W Kriwacki Journal: EMBO J Date: 2004-12-16 Impact factor: 11.598
Authors: Jana N Radin; Carlos J Orihuela; Gopal Murti; Christopher Guglielmo; Peter J Murray; Elaine I Tuomanen Journal: Infect Immun Date: 2005-12 Impact factor: 3.441
Authors: Lei Hu; Sangeeta B Joshi; Mangala Roshan Liyanage; Mekala Pansalawatta; Mark R Alderson; Andrea Tate; George Robertson; Jeff Maisonneuve; David B Volkin; C Russell Middaugh Journal: J Pharm Sci Date: 2012-11-18 Impact factor: 3.534
Authors: Scott A Brown; John Stambas; Xiaoyan Zhan; Karen S Slobod; Chris Coleclough; Amy Zirkel; Sherri Surman; Stephen W White; Peter C Doherty; Julia L Hurwitz Journal: J Immunol Date: 2003-10-15 Impact factor: 5.422
Authors: Muna F Abry; Kelvin M Kimenyi; Fred O Osowo; Willingtone O Odhiambo; Steven O Sewe; Benard W Kulohoma Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Melinda M Pettigrew; Mark R Alderson; Lauren O Bakaletz; Stephen J Barenkamp; Anders P Hakansson; Kevin M Mason; Johanna Nokso-Koivisto; Janak Patel; Stephen I Pelton; Timothy F Murphy Journal: Otolaryngol Head Neck Surg Date: 2017-04 Impact factor: 3.497
Authors: Austen Chen; Beth Mann; Geli Gao; Richard Heath; Janice King; Jeff Maissoneuve; Mark Alderson; Andrea Tate; Susan K Hollingshead; Rodney K Tweten; David E Briles; Elaine I Tuomanen; James C Paton Journal: Clin Vaccine Immunol Date: 2015-08-05